期刊文献+

缺失半胱氨酸富集区的HIV-1 HXB2株Tat蛋白在大肠杆菌中的高效表达及免疫原性分析 被引量:5

Effective expression and immunogenicity analysis of HIV-1 HXB2 subtype Tat protein deleted the cysteine-rich region in E. coli
原文传递
导出
摘要 目的删除人免疫缺陷病毒Ⅰ型(HIV-1)HXB2株Tat罗白(长度101个氨基酸)的半胱氨酸富集区(22~37位氨基酸)以提高其在大肠杆菌中的表达量因子稳定性,并分析缺失半胱氨酸富集区后的Tat蛋白[Tat(ΔC)蛋白]免疫原性的改变。方法应用PCR方法对Tat基因的半胱氨酸富集区(64—111位核苷酸)进行缺失突变,获得其突变体序列[Tat(ΔC)DNA],并构建其重组表达质粒pET-32a-Tat(ΔC)。相同的条件下将pET-32a-Tat(Δc)和pET-32a.Tat质粒转人大肠杆菌B121(DE3)中进行诱导表达及纯化。用pET-32a-Tat(ΔC)融合蛋白免疫家兔制备抗血清,ELISA和Western blot方法对抗血清进行免疫原性分析。结果pET-32a-Tat(ΔC)蛋白在大肠杆菌中的表达水平(7.12mg/m1)明显高于pET-32a-Tat蛋白(1.50mg/m1);pET-32a-Tat蛋白在表达纯化后及25℃和4℃放置7d后均有明显二聚体的产生,而pET-32a-Tat(ΔC)蛋白则未形成二聚体;pET-32a-Tat(Δc)蛋白免疫家兔可诱导产生高滴度的抗体(1:320000),该抗体与Tat(Δc)蛋白、Tat蛋白(1—101AA)及化学合成Tat(1~86AA)蛋白均呈特异性反应。结论缺失HIV-1 Tat蛋白的半胱氨酸富集区可明显提高其原核表达水平和蛋白的稳定性并较好地保留其免疫原性,为HIV-1 Tat疫苗研究提供了一种新型免疫原。 Objective Deleting the cysteine-rich region (22-37 amino acids)of HIV-1 HXB2 Tat protein( whole length is 101 amino acids) to improve its stability and expression level in E. coli and to analyze the immunogenicity of Tat protein without the cystein-rich region [ Tat( Δ C) protein ]. Methods Tat DNA deleted the cysteine-rich region (64-111 nucleotides), named as Tat(ΔC) DNA, was obtained in vitro by PCR and cloned into pET-32a vector, pET-32a-Tat(Δ C)plasmid and the pET-32a-Tat plasmid were established and transformed into E. coli BL21 ( DE3 ) strains respectively to express and purify the protein. Three rabbits were vaccinated with pET-32a-Tat( Δ C)protein, then testify the reactivity of sera from rabbits by ELISA and Western blot. Results The dense of the purified pET-32a-Tat (ΔC) protein was 7. 12 mg/ml, which was greatly more than pET-32a-Tat protein( 1.50 mg/ml). Dimer of pET-32a-Tat protein can be observed just after the protein purification and stored at 25℃ and 4℃ for 7 days, but dimer of pET-32a- Tat(ΔC) protein was not formed at the same condition. Experimental rabbits were immunized with pET-32a- Tat(Δ C)protein and produced high titre of anti-pET-32a-Tat( Δ C )serum ( 1:320 000), the antibody can react specifically with Tat(ZXC) protein, Tat protein ( 1-101 AA) and synthetic Tat( 1-86 AA) protein. De- letion mutation of the cysteine-rich region of Tat protein was first performed in the study. Conclusion The expression level in E. coli and the stability of Tat protein deleted the cysteine-rich region can be increased greatly, and the protein remains good immunogenicity. The results may provide a novel antigen for further development of HIV-1 Tat vaccine.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2008年第5期404-410,共7页 Chinese Journal of Microbiology and Immunology
基金 国家自然科学基金资助项目(30472050) 上海市科技攻关项目(05dz19317)
关键词 人免疫缺陷病毒Ⅰ型 半胱氨酸富集区缺失 TAT蛋白 Human immunodeficiency virus type-1 Deletion of cysteine-rich region Tat protein
  • 相关文献

参考文献20

  • 1Apolloni A. Hooker CW, Mak J, et al. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol, 2003, 77 (18) : 9912-9921.
  • 2Li CJ, Friedman D J, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science, 1995, 268 (5209) : 429-431.
  • 3Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma associated herpesvirus ( KSHV ) infectivity. Blood, 2004, 104 ( 3 ) : 810-814.
  • 4艾菁,王丽梅,夏威,耿美玉.Tat蛋白结构与功能的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):133-135. 被引量:17
  • 5Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem, 1999, 274 (41): 28837-28840.
  • 6Ensoli B, Fiorelli V, Ensoli F, et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS, 2006, 20(18) : 2245-2261.
  • 7Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol, 1998, 1 (4) : 282-292.
  • 8Belliard G, Hurtrel B, Moreau E, et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine, 2005, 23 ( 11 ) : 1399-1407.
  • 9Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: the human immunodeficiency virus ( HIV ). Vaccine, 2006, 24(19): 4062-4081.
  • 10林剑萍,王华,王玲,卫红飞,胡晓平,王丽颖,于永利.HIV-1Tat基因的融合构建及在大肠杆菌中的高效表达[J].细胞与分子免疫学杂志,2005,21(1):33-36. 被引量:6

二级参考文献34

  • 1吴玉章,朱锡华.分子设计及其在免疫学中的应用展望[J].免疫学杂志,1993,9(1):1-3. 被引量:6
  • 2Chang HC, Samaniego F, Nair BC, et al. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix associated heparan sulphate proteoglycans through its basic region[J]. AIDS, 1997, 11: 1421-1431.
  • 3Chang HK, Gallo RC, Ensoli B. Regulation of gene expression and cellular function by human immunodeficiency virus type 1 protein[J]. Biomed Sci, 1995, 2: 189-202.
  • 4Li CJ, Friedman DJ, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein[J]. Science, 1995, 268: 4294-4301.
  • 5Fiorelli VG, Barillari E, Toschi C, et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to HIV-1 Tat protein: implications for AIDS-Kaposi's sarcoma pathogenesis[J]. Immunology, 1999, 162: 1165-1171.
  • 6Epstein LG, Gelbard HA. HIV-1-induced neuronal injury in the developing brain[J]. Leukoc Biol, 1999, 65: 453-457.
  • 7Gething MJ, Sambrook J. Protein folding in the cells[J]. Nature, 1992, 335: 6355-6359.
  • 8Levy GR, Viitanen P, Weiss C, et al. The effect of nucleotides and mitochondrial chaperonin 10 on the structure and chaperone activity of mitochondrial chaperonin 60[J]. Eur J Biochem, 2001, 268: 3465-3472.
  • 9Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat [ J ]. J Biol Chem, ( Review ).1999, 274(41): 28837-28840.
  • 10Rana TM, Jeang KT. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA[J]. Arch Biochem Biophys, (Review). 1999, 365(2) : 175 -185.

共引文献23

同被引文献53

  • 1林剑萍,于永利,王丽颖.细胞外HIV Tat蛋白的致病作用及其疫苗研究进展[J].国外医学(免疫学分册),2005,28(2):76-79. 被引量:4
  • 2艾菁,王丽梅,夏威,耿美玉.Tat蛋白结构与功能的研究进展[J].细胞与分子免疫学杂志,2005,21(B03):133-135. 被引量:17
  • 3蒋卫民,卢洪洲,潘孝彰,康来仪,尹春煜,胡越凯,翁心华.HIV-1 p24和gp41融合基因表达载体的构建及融合蛋白的表达纯化[J].中华传染病杂志,2005,23(3):170-173. 被引量:2
  • 4Apolloni A, Hooker C W, Mak J, et al. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication [ J ]. J Virol, 2003,77(18) :9912 -21.
  • 5Aoki Y, Tosato G. HIV-I Tat enhances Kaposi sarcoma associated herpesvirus (KSHV) infectivity [J]. Blood, 2004, 104 (3) :810 -4.
  • 6Fiorelli V G, Barillari E, Toschi C, et al. IFN gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to HIV-1 Tat protein: implications for AIDS Kaposi' s sarcoma pathogenesis[ J ]. Immunology, 1999,162 ( 2 ) : 1165 - 70.
  • 7Epstein L G, Gelbard H A. HIV-1 induced neuronal injury in the developing brain[J]. Leukoc Biol, 1999,65(4) :453 -7.
  • 8Zagury J F, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat Toxoid as an HIV-1 vaccine[J]. J Hum Virol, 1998,1(4):282 -92.
  • 9Belliard G, Hurtrel B, Morean E, et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides [ J ]. Vaccine,2005,23 (11 ) : 1399 - 407.
  • 10Kittiworakarn J, Lecoq A, Moine G, et al. HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers[ J]. J Biol Chem,2006,281 (6) :3105 - 15.

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部